"Creation of the
Members of the
Greg Elliot, M.D., MACP, Medical Director of the Pulmonary Hypertension Center and Chairman of the Department of Medicineat Intermountain Medical Centerand Professor of Medicine at the University of Utah
Nazzareno Galie, M.D., Head of the Pulmonary Hypertension Center at the University of Bologna
Ardeschir Ghofrani, M.D., Associate Professor for Internal Medicine and Head of the Pulmonary Hypertension Division at
University Hospital, Giessen
Fernando Martinez, M.D., Executive Vice Chair of Medicine at the Weill Cornell Medical Collegeand New York-Presbyterian Hospital/Weill Cornell Medical Center
Vallerie McLaughlin, M.D., Professor of Medicine and Director of the Pulmonary Hypertension Program at the University of Michigan; Attending Physician at the University of Michigan Health Systemin Ann Arbor, Michigan
Robert Naeije, M.D., Ph.D, Professor and Chairman of the
Department of Physiology and Pathophysiologyat Erasme University Hospital, Brussels
Steve Rennard, M.D., Larson Professor of Medicine in the Pulmonary and Critical Care Medicine, Department of Internal Medicineat the University of Nebraska Medical Centerin Omaha
Lewis Rubin, M.D., FACP, FCCP, FAHA, FRCP, Emeritus Professor of Medicine and Emeritus Director of Pulmonary and Critical Care at the University of California in San Diego
Olivier Sitbon, M.D., Ph.D., Professor of Respiratory Medicine at the South Paris University
INOpulse is Bellerophon's proprietary pulsatile nitric oxide drug-device combination technology for the treatment of pulmonary hypertension in the chronic outpatient setting. Two of the Company's programs using this technology are currently in development – one for the treatment of PAH is expected to begin Phase 3 trials later this year, and a second for the treatment of PH-COPD is being evaluated for a Phase 2b trial.
Nitric oxide is naturally produced and released by portions of the blood vessels and results in smooth muscle relaxation. In particular, nitric oxide controls muscle tone in blood vessels and, thus, is an important factor in regulating blood pressure. As the muscles of the blood vessels relax, blood flow increases, helping the heart to deliver more blood to the body.
Any statements in this press release about Bellerophon's future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Any forward-looking statements represent Bellerophon's views only as of the date of this press release. Bellerophon anticipates that subsequent events and developments will cause its views to change. While Bellerophon may elect to update these forward-looking statements at some point in the future, Bellerophon specifically disclaims any obligation to do so.
CONTACT: At Bellerophon:
Manesh Naidu, Chief Business Officer (908) 574-4770 At Rx Communications Group: Paula Schwartz(Investors) (917) 322-2216 Eric Goldman(Media) (917) 322-2563 egoldman@RxIR.com